ISSN 1662-4009 (online)

ey0016.2-8 | Neonatal Diabetes Mellitus | ESPEYB16

2.8. Effectiveness and safety of long-term treatment with sulfonylureas in patients with neonatal diabetes due to KCNJ11 mutations: an international cohort study

P Bowman , AE Sulen , F Barbetti , J Beltrand , P Svalastoga , E Codner , EH Tessmann , PB Juliusson , T Skrivarhaug , ER Pearson , SE Flanagan , T Babiker , NJ Thomas , MH Shepherd , S Ellard , I Klimes , M Szopa , M Polak , D Iafusco , AT Hattersley , PR Njolstad , Neonatal Diabetes International Collaborative Group. Collaborators (113)

To read the full abstract: Lancet Diabetes Endocrinol. 2018 Aug;6(8)This study describes a 10-year follow-up of a large international multicenter cohort of patients with KCNJ11 permanent neonatal diabetes. It addresses key questions relating to long-term efficacy and safety of sulfonylureas in these patients.The discovery that mutations in the KCNJ11</...

ey0015.14-14 | Reliable evidence on mouse knock-outs | ESPEYB15

14.14 Disease model discovery from 3,328 gene knockouts by The International Mouse Phenotyping Consortium

TF Meehan , N Conte , DB West , JO Jacobsen , J Mason , J Warren , CK Chen , I Tudose , M Relac , P Matthews , N Karp , L Santos , T Fiegel , N Ring , H Westerberg , S Greenaway , D Sneddon , H Morgan , GF Codner , ME Stewart , J Brown , N Horner , C International Mouse Phenotyping , M Haendel , N Washington , CJ Mungall , CL Reynolds , J Gallegos , V Gailus-Durner , T Sorg , G Pavlovic , LR Bower , M Moore , I Morse , X Gao , GP Tocchini-Valentini , Y Obata , SY Cho , JK Seong , J Seavitt , AL Beaudet , ME Dickinson , Y Herault , W Wurst , MH de Angelis , KCK Lloyd , AM Flenniken , LMJ Nutter , S Newbigging , C McKerlie , MJ Justice , SA Murray , KL Svenson , RE Braun , JK White , A Bradley , P Flicek , S Wells , WC Skarnes , DJ Adams , H Parkinson , AM Mallon , SDM Brown , D Smedley

To read the full abstract: Nat Genet 2017;49:1231-1238This large international initiative is a major collaboration across 25 research institutes that was set up as part of the scientific community’s response to concerns regarding the notoriously poor reproducibility of scientific research. Up to now, many mouse gene knock-outs have been made and reported, but inconsistency between finding...

ey0018.13-5 | Diabetes | ESPEYB18

13.5. Access to insulin delivery devices and glycated haemoglobin in lower-income countries

EL Klatman , GD Ogle

World J Diabetes 2020; 11: 358–369. https://dx.doi.org/10.4239/wjd.v11.i8.358– To assess access to insulin delivery devices and HbA1c in 41 countries supported by the Life for a Child (LFAC) program– Syringes (83.1%), insulin pens (16.7%) and pumps (0.2%) were used for insulin delivery– If supplies were not donated, there was variable access to HbA1c testing within publi...

ey0016.13-5 | Diabetes | ESPEYB16

13.5. Blood glucose meters and test strips: Global market and challenges to access in low-resource settings

EL Klatman , AJ Jenkins , MY Ahmedani , GD Ogle

Lancet Diabetes Endocrinol 2019; 7: 150–60. DOI 10.1016/S2213-8587(18)30074-3• Access to blood glucose monitoring is often poor in resource-limited settings.• The authors analyse the reasons for suboptimal access, with a focus on cost, availability, system accuracy, competitive bidding, technological trends, and non-financial barriers. Urine gl...

ey0020.11-6 | Diabetes | ESPEYB20

11.6. Treatment of diabetic ketoacidosis with subcutaneous regular insulin in a non-ICU setting is effective and economical: A single-center experience

A Ayyavoo , A Ravikulan , R Palany

Brief summary: Since 2014, children with DKA have been managed on the general ward (instead of the intensive care unit [ICU]) and with SC insulin (instead of IV insulin) at G Kuppuswamy Naidu Memorial Hospital in Coimbatore, India. This retrospective study compares the cost and outcomes of IV (2013–2014) and SC insulin treatment (2017).In high-income countries (HICs), DKA management commonly includes IV insulin. The 2022 ISPAD Clinical Practice Cons...